View in EDS

Psychedelic Therapeutics for Adolescents: Ethics, Safety, Opportunities, and Equipoise.

Saved in:
Bibliographic Details
Title: Psychedelic Therapeutics for Adolescents: Ethics, Safety, Opportunities, and Equipoise.
Authors: Croarkin, Paul E.1 (AUTHOR) croarkin.paul@mayo.edu, Sutherland, Isabella2 (AUTHOR), Ho, Ming-Fen1 (AUTHOR)
Source: Journal of the American Academy of Child & Adolescent Psychiatry. Jul2025, Vol. 64 Issue 7, p756-758. 3p.
Subject Terms: *Teenagers, LSD (Drug), Medical research, Psilocybin, Clinical trials
Abstract: We read with great interest the commentary by Jeffrey et al. entitled "Clinical Research Trials of Psychedelic-Assisted Therapy in Adolescents Aged 16 to 17 Years: Rationale Balanced With Caution."1 We appreciate the efforts of the authors, the scholarship of this commentary, and the advocacy for research initiatives with psychedelic therapeutics such as psilocybin, lysergic acid diethylamide, and 3,4-methylenedioxymethamphetamine. We agree that there is a compelling rationale for timely, rigorous studies with adolescents as it is likely that these compounds have been and will be used in adolescents with therapeutic intent. We are writing to catalyze further collegial dialogue and advocacy in our field. We do have some considerations for the authors. [ABSTRACT FROM AUTHOR]
Copyright of Journal of the American Academy of Child & Adolescent Psychiatry is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Education Research Complete
FullText Text:
  Availability: 0
Header DbId: ehh
DbLabel: Education Research Complete
An: 185625544
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Psychedelic Therapeutics for Adolescents: Ethics, Safety, Opportunities, and Equipoise.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Croarkin%2C+Paul+E%2E%22">Croarkin, Paul E.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<i> croarkin.paul@mayo.edu</i><br /><searchLink fieldCode="AR" term="%22Sutherland%2C+Isabella%22">Sutherland, Isabella</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Ho%2C+Ming-Fen%22">Ho, Ming-Fen</searchLink><relatesTo>1</relatesTo> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Journal+of+the+American+Academy+of+Child+%26+Adolescent+Psychiatry%22">Journal of the American Academy of Child & Adolescent Psychiatry</searchLink>. Jul2025, Vol. 64 Issue 7, p756-758. 3p.
– Name: Subject
  Label: Subject Terms
  Group: Su
  Data: *<searchLink fieldCode="DE" term="%22Teenagers%22">Teenagers</searchLink><br /><searchLink fieldCode="DE" term="%22LSD+%28Drug%29%22">LSD (Drug)</searchLink><br /><searchLink fieldCode="DE" term="%22Medical+research%22">Medical research</searchLink><br /><searchLink fieldCode="DE" term="%22Psilocybin%22">Psilocybin</searchLink><br /><searchLink fieldCode="DE" term="%22Clinical+trials%22">Clinical trials</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: We read with great interest the commentary by Jeffrey et al. entitled "Clinical Research Trials of Psychedelic-Assisted Therapy in Adolescents Aged 16 to 17 Years: Rationale Balanced With Caution."1 We appreciate the efforts of the authors, the scholarship of this commentary, and the advocacy for research initiatives with psychedelic therapeutics such as psilocybin, lysergic acid diethylamide, and 3,4-methylenedioxymethamphetamine. We agree that there is a compelling rationale for timely, rigorous studies with adolescents as it is likely that these compounds have been and will be used in adolescents with therapeutic intent. We are writing to catalyze further collegial dialogue and advocacy in our field. We do have some considerations for the authors. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Journal of the American Academy of Child & Adolescent Psychiatry is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=ehh&AN=185625544
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jaac.2024.12.003
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 3
        StartPage: 756
    Subjects:
      – SubjectFull: Teenagers
        Type: general
      – SubjectFull: LSD (Drug)
        Type: general
      – SubjectFull: Medical research
        Type: general
      – SubjectFull: Psilocybin
        Type: general
      – SubjectFull: Clinical trials
        Type: general
    Titles:
      – TitleFull: Psychedelic Therapeutics for Adolescents: Ethics, Safety, Opportunities, and Equipoise.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Croarkin, Paul E.
      – PersonEntity:
          Name:
            NameFull: Sutherland, Isabella
      – PersonEntity:
          Name:
            NameFull: Ho, Ming-Fen
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: Jul2025
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 08908567
          Numbering:
            – Type: volume
              Value: 64
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: Journal of the American Academy of Child & Adolescent Psychiatry
              Type: main
ResultId 1